Patents by Inventor Futao LIU

Futao LIU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PSMA INHIBITOR, COMPOUND AND APPLICATION
    Publication number: 20230414794
    Abstract: The present disclosure belongs to the technical field of biomedicine, and specifically relates to a PSMA inhibitor, compound and use thereof. The PSMA inhibitors having a novel core structure provided in the present disclosure has a wide range of potential applications.
    Type: Application
    Filed: January 21, 2020
    Publication date: December 28, 2023
    Inventors: Xing YANG, Zhi YANG, Zhen XI, Futao LIU, Xiaojiang DUAN
  • NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATION
    Publication number: 20210346526
    Abstract: The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 26, 2021
    Publication date: November 11, 2021
    Inventors: Zehui WU, Zhihao ZHA, Futao LIU, Karl PLOESSL, Seok Rye CHOI, Hank F. KUNG
  • Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application
    Patent number: 11071794
    Abstract: The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: July 27, 2021
    Assignee: Five Eleven Pharma Inc.
    Inventors: Zehui Wu, Zhihao Zha, Futao Liu, Karl Ploessl, Seok Rye Choi, Hank F. Kung
  • Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application
    Patent number: 10912849
    Abstract: The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: February 9, 2021
    Assignee: FIVE ELEVEN PHARMA INC.
    Inventors: Zehui Wu, Zhihao Zha, Futao Liu, Karl Ploessl, Seok Rye Choi, Hank F. Kung
  • NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATION
    Publication number: 20200230263
    Abstract: The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 19, 2020
    Publication date: July 23, 2020
    Applicant: Five Eleven Pharma Inc.
    Inventors: Zehui WU, Zhihao ZHA, Futao LIU, Karl PLOESSL, Seok Rye CHOI, Hank F. KUNG
  • NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATION
    Publication number: 20180344882
    Abstract: The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 31, 2018
    Publication date: December 6, 2018
    Inventors: Zehui WU, Zhihao ZHA, Futao LIU, Karl PLOESSL, Seok Rye CHOI, Hank F. KUNG